Straits Times Index
3,309.34 +9.34 (+0.28%) Nikkei
38,602.72 -30.30 (-0.08%) Hang Seng
18,064.74 -270.58 (-1.48%) FTSE 100
8,272.46 +67.35 (+0.82%) Bitcoin USD
64,590.28 -938.86 (-1.43%) CMC Crypto 200
1,352.89 -7.43 (-0.55%)
JNJ Jan 2025 250.000 put
- PR Newswire
Johnson & Johnson submits application to U.S. FDA seeking approval of TREMFYA® (guselkumab) for the treatment of moderately to severely active Crohn's disease
Johnson & Johnson (NYSE: JNJ) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval of TREMFYA® (guselkumab) for the treatment of adults with moderately to severely active Crohn's disease. This marks the second submission to the FDA for TREMFYA® in inflammatory bowel disease this year following an application in March for moderately to severely active ulcerative colitis.a
- PR Newswire
TREMFYA® (guselkumab) studies underscore its potential to be the only IL-23 inhibitor to offer both subcutaneous and intravenous induction
Johnson & Johnson (NYSE: JNJ) today announced positive topline results from the pivotal Phase 3 GRAVITI investigational study of TREMFYA® (guselkumab) subcutaneous (SC) induction therapy in adult patients with moderately to severely active Crohn's disease.1 The study met both co-primary endpoints, achieving statistically significant and clinically meaningful outcomes for clinical remission at Week 12 as well as endoscopic response at Week 12. All remaining multiplicity-controlled secondary endpo
- Simply Wall St.
Johnson & Johnson Insiders Sell US$4.8m Of Stock, Possibly Signalling Caution
In the last year, many Johnson & Johnson ( NYSE:JNJ ) insiders sold a substantial stake in the company which may have...
